1.Black Diamond Therapeutics. (2024, September).Black Diamond Therapeutics Announces Preliminary Phase 2 Data from BDTX-1535 Trial in Patients with EGFR-Mutant NSCLC. [Press release]. Retrieved from Black Diamond 官网 2.Chou, J. F., et...
“We’ve seen some preliminary evidence of activity and we’ve gotten to some effective doses in the current clinical studies,” Spira said. The maximum tolerated dose was determined to be 300 mg daily and the dose escalation portion of the study consisted of a daily oral dose of BD...
The fourth-generation EGFR TKI BDTX-1535 yielded robust clinical activity and durability in patients with relapsed/refractory, EGFR-mutant non–small cell lung cancer (NSCLC) harboring classical, non-classical, or C797S resistance mutations, according to ini...
2069#Background:This Phase 0/1 clinical trial evaluates the pharmacokinetic (PK), pharmacodynamic (PD), and clinical response of recurrent high-grade glioma (HGG) patients with EGFR alterations and/or fusions to the ATP-competitive, irreversible EGFR inhibitor, BDTX-1535.Methods:Recurrent HGG ...
Black Diamond also presented two additional posters outlining the study design of the ongoing Phase 1 clinical trial of BDTX-1535 in NSCLC and preclinical data for BDTX-4933, a brain-penetrant MasterKey RAF inhibitor targeting KRAS, ...
M.D., Ph.D., Chief Executive Officer ofBlack Diamond Therapeutics. “We believe that the activity observed in the recurrent setting can translate to robust clinical benefit in the first-line setting, and we look forward to sharing data from our trial in newly diagnosed patients ...
For additional information, please contactBDTX_1535_101_Study@bdtx.com.Clinical trial information: NCT05256290.Melissa Lynne JohnsonLung Cancer Research, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TNJason Timothy HenrySarah Cannon Research Institute at HealthONE, Denver, COAlexander I...
This Phase 0/1 study evaluates pharmacokinetic (PK), pharmacodynamic (PD), and clinical response to an ATP-competitive, irreversible EGFR inhibitor, BDTX-1535, in recurrent HGG patients with EGFR alterations and/or fusions. MATERIALS/METHODS Recurrent HGG patients with EGFR alterations (Arm A) or...
Dr Halmos discusses the ongoing investigation of the potent, selective, and irreversible EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.
Given the inability to reconfirm EGFR status at the time of treatment with BDTX-1535 in this Phase 1 trial, further exploration of BDTX-1535 in a "window of opportunity" study is ongoing (NCT06072586).Clinical trial information: NCT05256290.Patrick Y. Wen...